Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233264 | 0.83 | EPHX1 (0.50) | CYP1A2PTGS1SLC6A2SLC6A3LAP3 | |
| SCHEMBL9332536 | 0.82 | LTA4H (0.61) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL14279482 | 0.81 | LTA4H (0.61) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL7434755 | 0.81 | LTA4H (0.61) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL7426754 | 0.81 | LTA4H (0.61) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL41221 | 0.79 | LMNA (0.51) | BCHEMAOBLMNACYP1A2PTGS1 | |
| SCHEMBL28779138 | 0.78 | PPARG (0.52) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL11302697 | 0.78 | PPARG (0.65) | LTA4HPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL5270401 | 0.77 | BCHE (0.51) | BCHELTA4HPPARGPPARAFFAR1 | |
| SCHEMBL13110181 | 0.77 | BCHE (0.51) | BCHELTA4HPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627704-B | Preparation method of bazedoxifene | 艾瑞吉瑞股份公司 | 2024-02-23 | — | — | CN | disclosed |
| US-10844047-B2 | Process for the preparation of bazedoxifene | ERREGIERRE S.P.A. (IT) | 2020-11-24 | — | — | US | disclosed |
| CN-110627704-A | Preparation method of bazedoxifene | 艾瑞吉瑞股份公司 | 2019-12-31 | — | — | CN | disclosed |
| EP-1915364-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007020388-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1718617-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005080343-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844047-B2 | Process for the preparation of bazedoxifene | CYP19A1, CYP3A5, CYP4A11 | BCHE 172/4885LTA4H 884/4885PPARG 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.